drugset / Trial / NCT04221503
Niraparib/TTFields in GBM
Phase 2
Active not recruiting
30 enrolled
Abramson Cancer Center at Penn Medicine
NovoCure Ltd. · collabTesaro, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
Timeline
- Start
- 2019-12-30
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 100 mg | Oral |